Nissay Asset Management Corp Japan Sells 14,506 Shares of Thermo Fisher Scientific Inc. $TMO

Nissay Asset Management Corp Japan lowered its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.6% during the second quarter, HoldingsChannel reports. The firm owned 84,909 shares of the medical research company’s stock after selling 14,506 shares during the quarter. Nissay Asset Management Corp Japan’s holdings in Thermo Fisher Scientific were worth $42,570,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Field & Main Bank bought a new stake in Thermo Fisher Scientific during the 2nd quarter worth approximately $859,000. Lombard Odier Asset Management Europe Ltd acquired a new position in shares of Thermo Fisher Scientific in the second quarter valued at approximately $18,456,000. Archer Investment Corp bought a new stake in shares of Thermo Fisher Scientific during the second quarter worth $490,000. Kingsview Wealth Management LLC acquired a new stake in shares of Thermo Fisher Scientific during the second quarter worth $3,881,000. Finally, Beacon Pointe Advisors LLC bought a new stake in Thermo Fisher Scientific in the 2nd quarter valued at $18,906,000. 89.23% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on TMO shares. Sanford C. Bernstein began coverage on Thermo Fisher Scientific in a report on Friday, June 26th. They set a “market perform” rating and a $520.00 target price for the company. Evercore set a $570.00 price objective on Thermo Fisher Scientific in a research report on Monday, July 6th. Jefferies Financial Group reiterated a “buy” rating and set a $630.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. Piper Sandler boosted their target price on Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a “neutral” rating in a research note on Monday, July 27th. Finally, KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $619.41.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $621.87 on Friday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The business has a 50-day moving average of $558.64 and a 200-day moving average of $512.08. The stock has a market capitalization of $229.94 billion, a price-to-earnings ratio of 33.45, a PEG ratio of 2.57 and a beta of 0.85. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $647.00.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.Thermo Fisher Scientific’s revenue was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.11%.

Insiders Place Their Bets

In related news, EVP Michael D. Shafer sold 25,500 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the transaction, the executive vice president directly owned 20,994 shares in the company, valued at approximately $12,596,400. The trade was a 54.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 11,440 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the sale, the vice president directly owned 14,784 shares in the company, valued at $9,064,366.08. This trade represents a 43.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 73,768 shares of company stock valued at $44,122,820 in the last ninety days. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.